Biotechnology

CSafe unveils cutting-edge innovations to meet cold chain customer needs

The company will launch three new technologies at the upcoming LogiPharma 2024 event MONROE, Ohio, April 10, 2024 /PRNewswire/ -- CSafe, a leading active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announces it is launching three new technol...

2024-04-10 22:50 654

Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics

SUZHOU, China, April 10, 2024 /PRNewswire/ -- IBD, or Inflammatory Bowel Disease, traditionally more prevalent in developed nations, is increasingly observed in developing regions likeChina. It is a chronic, nonspecific inflammatory gastrointestinal disorder with an unknown etiology, characterize...

2024-04-10 21:15 656

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

NEWARK, Del., April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, including the 2024 International Organoid Summit, the Alzheimer's Research UK Conferenc...

2024-04-10 21:00 619

MGI Tech Presents Latest Storage Product Series at ISBER 2024

MELBOURNE, Australia, April 10, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, today showcased its latest storage solutions catering to a variety of sample storage needs, including MGICLab-LT*, MGICLab-LN55K*, and M...

2024-04-10 17:18 734

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

BEIJING and PARIS, April 10, 2024 /PRNewswire/ -- On March 15th, Biologics 2024 successfully concluded inLondon, with 650 pharmaceutical, biotechnology, and academic representatives and over 50 exhibitors engaging in high-level discussions on the latest innovations in biologics discovery and deve...

2024-04-10 14:19 655

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

TOKYO, April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been launching a continuous stream of innovative organoid-related products. Displaying their advancements at key global forums including the 2024 International Organoid Summit, Alzheimer's Research UK Conference 2024, and ...

2024-04-10 14:05 902

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first p...

2024-04-10 11:41 1099

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR

* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100...

2024-04-10 08:40 1084

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...

2024-04-09 23:14 1228

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...

2024-04-09 22:10 925

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-09 20:00 848

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...

2024-04-09 19:59 666

GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...

2024-04-09 19:00 1115

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent  * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...

2024-04-09 17:52 1010

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

News Summary: * New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. * Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted anal...

2024-04-09 14:00 1005

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilen...

2024-04-09 09:18 1037

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...

2024-04-09 08:30 935

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...

2024-04-08 22:00 857

Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"

* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...

2024-04-08 20:00 1344

SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego

Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds in Retrospective and Prospective Settings Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict the Tissue of Origin of Ca...

2024-04-08 20:00 818
12345 ... 277